Organizers and Facilitators: Sunil Kripalani, MD, MSc; Lana Wahid, MD; Andy Auerbach, MD, MPH
Background: HOMERuN was founded as a learning health organization and has engaged in many multi-center collaborations, but not previously in multi-center clinical trials. Conducting pragmatic randomized controlled trials (pRCTs) is a promising new strategy for HOMERuN to generate rigorous real-world evidence on topics relevant to clinical practice, while also growing research infrastructure, providing career development opportunities, and opening new funding streams. pRCTs can be conducted in a way that largely utilizes electronic procedures for patient identification, randomization, and outcome assessment. These types of pRCTs can be used to compare the effectiveness of two standards of care (e.g., the recent ACORN trial, which compared cefipime vs piperacillin-tazobactam in adults with acute infection), or compare different strategies for implementing practice change (e.g., a mentored implementation model vs clinical decision support).
At Vanderbilt, a pragmatic trials group has successfully carried out single-site pRCTs, and has spread the approach to conduct multi-center pRCTs through the Pulmonary Critical Care Research Group. At Duke, the hospitalist group has built up capacity and developed efficient procedures to perform RCTs. UCSF has built out specific research infrastructure to support EHR-based randomized trials and is helping develop multicenter RCT informatics infrastructure.
To explore the extension of these models to HOMERuN, we conducted break out sessions during the January 12 Collaborative Call, asking participants to weigh in on a few key questions:
- What is the level of interest in participating in a pragmatic clinical trials network?
- What infrastructure is currently available at HOMERuN sites for pragmatic trials?
- Does this infrastructure reside within (or is easily accessed by) hospital medicine? If not, is it available at the institution?
- What support would be needed for successful participation in a pragmatic trials network?
Below is a summary of the major themes that emerged in the discussion.